| Publisher's Note: FierceBiotech won't be in your inbox next week, but we will be covering breaking news on FierceBiotech.com. Our newsletters will return on Jan. 2. Happy holidays!
Today's Rundown Featured Story | | | Friday, December 21, 2018 As we near the end of the year, we like to take a look back over the biggest stories of 2018 and gauge what you, dear reader, found the most interesting, rewarding or controversial. This year, controversy and so-called negative news took precedent, although our biggest story by a large margin centered around Bill Gates and a new startup. |
|
|
| This week's sponsor is FierceBiotech. | |  | |
Top Stories Friday, June 8, 2018 The Bill & Melinda Gates Foundation has held a coming-out party for its nonprofit biotech startup. Equipped with plans to build a 120-person team and spend $100 million a year, the Gates Medical Research Institute will turn drug industry expertise and processes on intractable diseases that kill millions of people annually in low- and middle-income countries. Wednesday, June 13, 2018 During the BIO International Convention in Boston last week, an unaffiliated party featured topless dancers and models painted with the logos of investment firms and biotech companies sponsoring the event, incensing the chairman of the trade group to the point of reconsidering their memberships in the organization. Monday, December 17, 2018 Clinical research sites have a tough, but critically important, job. It’s rigorous and precise work, but essential to the progress of medicine. Sunday, January 7, 2018 A new journal paper published late last week revealed that a “cutting” element of the CRISPR-Cas9 gene-editing technique could be under threat from the body’s own immune system. Thursday, August 30, 2018 Pfizer halted two ongoing phase 2 trials of its Duchenne muscular dystrophy drug domagrozumab after the main efficacy study failed to meet its primary endpoint after one year of treatment. Monday, July 16, 2018 It’s an interesting trip, reading the comprehensive account of Theranos’ rise and fall, and that of its founder, Elizabeth Holmes—especially when taken as a careful watcher of the biotech industry or simply knowing the tale’s ending, such as it is. Tuesday, October 2, 2018 All of our Fierce 15 winners care deeply about biomedical science and understand the unique pressure to translate every penny they've raised into something truly innovative for patients. And it seems this passion is infectious when it comes to luring investors. Resources Sponsored by: DocuSign Life sciences companies must immediately identify and realize productivity gains to drive down operational costs—or risk seeing more nimble competitors disappear into the distance. Where to begin? Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Patheon, part of Thermo Fisher Scientific Read this whitepaper to learn how the biologics market is quickly evolving and how these changes pose several risks to a molecule’s success. Sponsored by: Coupa Software Learn how Becton Dickinson implemented Coupa to create an easy-to-use purchase to pay process that increased efficiency across the organization. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
